DICE Therapeutics - DICE Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DICE shares.
View DICE analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1-year target prices for DICE Therapeutics' shares. Their DICE share price forecasts range from $54.00 to $77.00. On average, they expect the company's stock price to reach $65.86 in the next twelve months. This suggests a possible upside of 139.8% from the stock's current price.
View analysts price targets for DICE or view top-rated stocks among Wall Street analysts.

DICE Therapeutics' stock was trading at $31.20 at the beginning of the year. Since then, DICE shares have decreased by 12.0% and is now trading at $27.46.
View the best growth stocks for 2023 here.

DICE Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 6,850,000 shares, an increase of 13.2% from the February 28th total of 6,050,000 shares. Based on an average daily trading volume, of 459,000 shares, the short-interest ratio is presently 14.9 days. Currently, 17.8% of the shares of the stock are short sold.
View DICE Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our DICE earnings forecast.

DICE Therapeutics, Inc. (NASDAQ:DICE) announced its quarterly earnings data on Friday, November, 12th. The company reported ($2.30) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $1.77.

ETFs with the largest weight of DICE Therapeutics (NASDAQ:DICE) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Clinical Trials ETF (BBC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

(DICE) raised $160 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share.

DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE."

DICE Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (14.37%), Price T Rowe Associates Inc. MD (6.75%), Sands Capital Ventures LLC (5.77%), Avoro Capital Advisors LLC (5.30%), Driehaus Capital Management LLC (4.10%) and Alkeon Capital Management LLC (2.18%). Insiders that own company stock include James Paul Scopa and Ra Capital Management, LP.
View institutional ownership trends.

Shares of DICE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DICE stock can currently be purchased for approximately $27.46.

DICE Therapeutics (NASDAQ:DICE) has a market capitalization of $1.31 billion and generates $1.13 million in revenue each year. The company earns $-83,890,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.dicemolecules.com. The company can be reached via phone at 650-566-1420 or via email at investors@dicetx.com.